Shield Therapeutics (LON:STX) Stock Price Up 15.5% – Still a Buy?

Posted by Lauren Steadman on Dec 5th, 2025

Shield Therapeutics plc (LON:STX – Get Free Report) shot up 15.5% on Tuesday . The stock traded as high as GBX 11.30 and last traded at GBX 11.20. 7,312,831 shares traded hands during mid-day trading, an increase of 160% from the average session volume of 2,813,147 shares. The stock had previously closed at GBX 9.70.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 15 price objective on shares of Shield Therapeutics in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of GBX 15.

View Our Latest Analysis on STX

Shield Therapeutics Stock Down 4.2%

The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The firm has a market capitalization of £119.98 million, a PE ratio of -5.65 and a beta of 1.42. The business has a 50-day moving average price of GBX 7.72 and a 200-day moving average price of GBX 5.70.

Shield Therapeutics Company Profile

(Get Free Report)

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.